Reduced NKG2D ligand expression in hepatocellular carcinoma correlates with early recurrence

被引:101
|
作者
Kamimura, Hiroteru
Yamagiwa, Satoshi [1 ]
Tsuchiya, Atsunori
Takamura, Masaaki
Matsuda, Yasunobu [2 ]
Ohkoshi, Shogo
Inoue, Makoto [3 ]
Wakai, Toshifumi [3 ]
Shirai, Yoshio [3 ]
Nomoto, Minoru
Aoyagi, Yutaka
机构
[1] Niigata Univ, Div Gastroenterol & Hepatol, Grad Sch Med & Dent Sci, Chuo Ku, Niigata 9518510, Japan
[2] Niigata Univ, Dept Med Technol, Sch Hlth Sci, Fac Med, Niigata 9518510, Japan
[3] Niigata Univ, Div Surg, Grad Sch Med & Dent Sci, Niigata 9518510, Japan
基金
日本学术振兴会;
关键词
ULBP; MICA; NK cell; Immune surveillance; Proteasome inhibitor; NATURAL-KILLER-CELL; I-RELATED CHAIN; GENE-EXPRESSION; NK CELLS; T-CELLS; RECEPTORS; PROGNOSIS; MOLECULES; PROTEINS; HEPATOMA;
D O I
10.1016/j.jhep.2011.06.017
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background 82 Aims: The activating receptor natural killer group 2, member D (NKG2D) and its ligands play a crucial role in immune response to tumors. NKG2D ligand expression in tumors has been shown to be associated with tumor eradication and superior patient survival, but the involvement of NKG2D ligands in the immune response against hepatocellular carcinoma (HCC) still remains to be elucidated. Methods: We investigated the expression of NKG2D ligands in HCC tissues collected from 54 patients and HCC cell lines. We also examined the proteasome expression and the effect of inhibition of proteasome activity on NKG2D ligand expression in HCC tissues and cell lines. Results: In dysplastic nodules (DN), well-differentiated (well-HCC), and moderately-differentiated HCCs (mod-HCC), UL16-binding protein (ULBP) 1 was expressed predominantly in tumor cells, but not in poorly-differentiated HCCs (poor-HCC). Remarkably, recurrence-free survival of patients with ULBP1-negative HCC was significantly shorter than that of patients with ULBP1-positive HCC (p = 0.006). Cox regression analysis revealed that loss of ULBP1 expression was an independent predictor of early recurrence (p = 0.008). We confirmed that ULBP1 was expressed in the well- and mod-HCC cell lines, but not in the poor-HCC cell line KYN-2. However, inhibition of proteasome activity resulted in significant up-regulation of ULBP1 expression in KYN-2. Moreover, we found that 20S proteasome expression was more abundant in KYN-2 than that in the well- and mod-HCC cell lines. Conclusions: ULBP1 is prevalently expressed in DN to mod-HCC, but loss of its expression correlates with tumor progression and early recurrence. (C) 2011 European Association for the Study of the Liver. Published by Elsevier By. All rights reserved.
引用
收藏
页码:381 / 388
页数:8
相关论文
共 50 条
  • [21] New prospects on the NKG2D/NKG2DL system for oncology
    Ullrich, Evelyn
    Koch, Joachim
    Cerwenka, Adelheid
    Steinle, Alexander
    ONCOIMMUNOLOGY, 2013, 2 (10):
  • [22] NKG2D Polymorphism in Melanoma Patients from Southeastern Spain
    Gimeno, Lourdes
    Martinez-Banaclocha, Helios
    Victoria Bernardo, M.
    Miguel Bolarin, Jose
    Marin, Luis
    Lopez-Hernandez, Ruth
    Rocio Lopez-Alvarez, M.
    Rosa Moya-Quiles, M.
    Muro, Manuel
    Francisco Frias-Iniesta, Jose
    Martinez-Escribano, Jorge
    Rocio Alvarez-Lopez, M.
    Minguela, Alfredo
    Antonio Campillo, Jose
    CANCERS, 2019, 11 (04)
  • [23] Prognostic significance and functional implication of immune activating receptor NKG2D in gastric cancer
    Lin, Fengjuan
    Dai, Congqi
    Ge, Xiaoxiao
    Tang, Wenbo
    Lin, Ying
    Wang, Yan
    Li, Jin
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2017, 487 (03) : 619 - 624
  • [24] The immunoreceptor NKG2D promotes tumour growth in a model of hepatocellular carcinoma
    Sheppard, Sam
    Guedes, Joana
    Mroz, Anna
    Zavitsanou, Anastasia-Maria
    Kudo, Hiromi
    Rothery, Stephen M.
    Angelopoulos, Panagiotis
    Goldin, Robert
    Guerra, Nadia
    NATURE COMMUNICATIONS, 2017, 8
  • [25] Recent Advances in Molecular Mechanisms of the NKG2D Pathway in Hepatocellular Carcinoma
    Wang, Jian
    Li, Cun-Di
    Sun, Lin
    BIOMOLECULES, 2020, 10 (02)
  • [26] NKG2D ligand tumor expression and association with clinical outcome in early breast cancer patients: an observational study
    de Kruijf, Esther M.
    Sajet, Anita
    van Nes, Johanna G. H.
    Putter, Hein
    Smit, Vincent T. H. B. M.
    Eagle, Robert A.
    Jafferji, Insiya
    Trowsdale, John
    Liefers, Gerrit Jan
    van de Velde, Cornelis J. H.
    Kuppen, Peter J. K.
    BMC CANCER, 2012, 12
  • [27] ULBP6/RAET1L is an additional human NKG2D ligand
    Eagle, Robert A.
    Traherne, James A.
    Hair, James R.
    Jafferji, Insiya
    Trowsdale, John
    EUROPEAN JOURNAL OF IMMUNOLOGY, 2009, 39 (11) : 3207 - 3216
  • [28] Prevalence of the NKG2D Thr72Ala Polymorphism in Patients with Cervical Carcinoma
    Roszak, Andrzej
    Lianeri, Margarita
    Jagodzinski, Pawel P.
    GENETIC TESTING AND MOLECULAR BIOMARKERS, 2012, 16 (08) : 841 - 845
  • [29] Sunitinib Induces NK-κB- dependent NKG2D Ligand Expression in Nasopharyngeal Carcinoma and Hepatoma Cells
    Huang, Yu-xian
    Chen, Xin-tong
    Guo, Kun-yuan
    Li, Yu-hua
    Wu, Bing-yi
    Song, Chao-yang
    He, Yan-jie
    JOURNAL OF IMMUNOTHERAPY, 2017, 40 (05) : 164 - 174
  • [30] Immunogenetics of the NKG2D ligand gene family
    Masanori Kasahara
    Shigeru Yoshida
    Immunogenetics, 2012, 64 : 855 - 867